🟢 TCRX Rises as TScan Therapeutics Announces Phase III Trial Launch for Lead Program TSC-101

TCRX is trading 5.6% up today at $1.03, extending a recent rebound.

• TScan Therapeutics announced the launch of its pivotal Phase III trial for its lead program, TSC-101, at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026.
• The company highlighted encouraging relapse-free survival results from Phase I data and a new commercial-ready manufacturing process for TSC-101.
• Recent analyst data maintains a generally bullish long-term outlook for the stock, with median price targets significantly above the current share price.